Canada Animal Model Market

Canada Animal Model Market Size Insights Forecasts to 2035

• The Canada Animal Model Market Size was estimated at USD 0.175 Billion in 2024
• The Market Size is Expected to Grow at a CAGR of around 7.15% from 2025 to 2035
• The Canada Animal Model Market Size is Expected to Reach USD 0.374 Billion by 2035

The Canada Animal Model Market Size is anticipated to Reach USD 0.374 Billion by 2035, Growing at a CAGR of 7.15% from 2025 to 2035. The growing use of animal models in biomedical research, neurology, genetics, toxicology, and cancer drives the business expansion. Moreover, some factors driving industry growth such as the rise of novel technologies like CRISPR in biomedical research and the expansion of R&D efforts by biopharmaceutical companies to develop novel therapeutics.

Market Overview

The deployment of animals for biomedical research and drug development for the study of disease mechanisms, to test the effectiveness of drugs, and ensure safety before human trials, is referred to as the animal model market. This is a branch of the Canadian branch of biotechnology industry. A live, non-human, genetically modified animal used for scientific research and disease analysis in humans. In addition, without causing harm to real individuals, these animal models are employed to gain a deeper comprehension of the human disease process. Their close relationship to human genetics, anatomy, and physiology makes them commonly chosen. They aid in collecting data regarding disease prevention, diagnosis, and treatment without endangering human health. Further, Canada's federal government launched a new strategy to reduce animal testing in regulatory labs, focusing on chemicals but excluding drugs and medical products. Moreover, the government is to find and encourage the use of scientifically sound substitutes for chemical testing on vertebrate animals, including dogs, cats, mice, and rabbits, as required by the Canadian Environmental Protection Act. The Canadian Institutes of Health Research (CIHR) is to develop specialised animal models, especially for research on infectious diseases, neurology, and oncology. A substantial amount of the 2.2 billion allotted has gone toward bolstering the infrastructure for preclinical research, including facilities for animal models.

Report Coverage

This research report categorises the market for the Canada animal model market based on various segments and regions, and forecasts revenue growth and analyses trends in each submarket. The report analyses the key growth drivers, opportunities, and challenges influencing the Canada animal model market. Recent market developments and competitive strategies, such as expansion, product launch, development, partnership, merger, and acquisition, have been included to draw the competitive landscape in the market. The report strategically identifies and profiles the key market players and analyses their core competencies in each sub-segment of the Canada animal model market.

Driving Factors

The Canadian animal model market is driven by several key factors driving its strong growth, like increasing investments in pharmaceutical and biotechnology R&D, amplifying demand for reliable animal models to conduct preclinical studies, particularly for oncology, neurology, immunology, and infectious diseases. Further, advances in gene editing technologies like CRISPR enable the creation of genetically engineered and humanised animal models that more accurately mimic human disease conditions, thereby enhancing drug development success rates. Canada's well-established life sciences infrastructure, strong academic and clinical research institutions, and government support through funding programs further encourage market expansion. Moreover, regulatory alignment with agencies such as the FDA and EMA accelerates research and clinical trial approvals involving animal studies.

Restraining Factors

Despite a significant market development, it suffers from some obstacles, such as regulations that necessitate extensive compliance, which drives up costs and delays for manufacturers and research institutions. Further, accessibility for smaller organisations is restricted by the high costs of breeding and maintaining specialised and genetically modified animal models, and fierce competition.

Market Segmentation

The Canada Animal Model market share is classified into application and end use.

• The cancer segment held a significant share in 2024 and is anticipated to grow at a rapid pace over the forecast period.

The Canada animal model market is segmented by application into cancer, immunological disease, infectious disease, and others. Among these, the cancer segment held a significant share in 2024 and is anticipated to grow at a rapid pace over the forecast period. This is because the application of animal models in preclinical studies and drug testing for evaluating the safety and effectiveness of anti-cancer treatments has grown exponentially. In addition, prior to moving on to human clinical trials, researchers can evaluate the therapeutic index, bioavailability, and pharmacokinetic characteristics of anticancer treatments using animal models.

• The pharmaceutical & biotechnology companies segment held a significant share in 2024 and is projected to grow at a rapid pace during the forecast period.

The Canada animal model market is segmented by end use into pharmaceutical & biotechnology companies, academic research institutes, and contract research organisations. Among these, the pharmaceutical & biotechnology companies segment held a significant share in 2024 and is projected to grow at a rapid pace during the forecast period. The segment is expected to grow as a result of companies' increased efforts to create innovative treatment plans. Additionally, it is anticipated that the numerous initiatives and research-driven pharmaceutical companies will support the growth of this segment.

Competitie Analysis:

The report offers the appropriate analysis of the key organisations/companies involved within the Canada animal model market, along with a comparative evaluation primarily based on their product offering, business overviews, geographic presence, enterprise strategies, segment market share, and SWOT analysis. The report also provides an elaborative analysis focusing on the current news and developments of the companies, which includes product development, innovations, joint ventures, partnerships, mergers & acquisitions, strategic alliances, and others. This allows for the evaluation of the overall competition within the market.

List of Key Companies

• Modelis Inc.
• VivoCore Inc
• AXYS Analytical Services
• BioLytical Laboratories
• NRC Human Health Therapeutics
• Charles River Laboratories Canada
• TransBIOTech
• Others

Recent Developments:

• In June 2023, ImmunoPrecise Antibodies (IPA) launched a HYFT-powered in silico humanisation platform designed to disrupt the transgenic animal model market. The outcome of IPA Canada's partnership with BioStrand, its subsidiary. By facilitating the early rejection of less promising therapeutic candidates, this novel approach seeks to greatly accelerate the early phases of drug discovery, saving time, money, and the chance of failure during later stages of discovery.

Key Target Audience

• Market Players
• Investors
• End-users
• Government Authorities 
• Consulting and Research Firm
• Venture capitalists
• Value-Added Resellers (VARs)

Market Segment

This study forecasts revenue at Canada, regional, and country levels from 2020 to 2035. Decisions Advisors has segmented the Canada Animal Model Market based on the below-mentioned segments:

Canada Animal Model Market, By Material Type

• Cancer
• Immunological Disease
• Infectious Disease
• Others

Canada Animal Model Market, By Process

• Pharmaceutical & Biotechnology Companies
• Academic Research Institute
• Contract Research Organisation